ASP Isotopes Inc.

ASP Isotopes Inc. is a development stage advanced materials company that focuses on the production, distribution, marketing, and sale of isotopes. It operates in two segments: Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment researches and develops technologies to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for advanced nuclear fuels. The Specialist Isotopes segment focuses on separating high-value, low-volume isotopes such as C-14, Mo-100, and Si-28 for pharmaceuticals, agrochemicals, nuclear medical imaging, and semiconductors. The company uses proprietary technologies, including the Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE), to separate isotopes. It also produces and commercializes isotopes like Molybdenum-100, Molybdenum-98, and Ytterbium-176 for nuclear medicine, and develops Zinc-68, Nickel-64, and Xenon-129/136 for the same industry. Additionally, it supplies isotopes for energy and semiconductor markets.

ASP Isotopes Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol ASPI. The company trades in United States Dollars (USD), as it is based in the United States and its primary listing is on a U.S. exchange. Being listed on Nasdaq provides the company with access to a broad base of investors and liquidity typical of major U.S. stock markets.

ASP Isotopes Inc. operates in the Basic Materials sector and is classified under the Chemicals industry. This classification reflects the company's focus on advanced materials, specifically isotopes, which are used in various industrial and scientific applications. As a chemicals company, ASP Isotopes deals with the separation and production of isotopic materials that serve as inputs for nuclear energy, medical imaging, pharmaceuticals, and semiconductor manufacturing. The Basic Materials sector encompasses companies that extract or process raw materials, and ASP Isotopes fits this description by processing and supplying specialized isotopes.

ASP Isotopes Inc. is headquartered in Dallas, Texas, United States. The company operates in South Africa, Hong Kong, and the United States. Its operations span multiple regions, leveraging the Aerodynamic Separation Process (ASP) technology and Quantum Enrichment (QE) technology to produce isotopes. The company's global footprint allows it to serve customers in various markets, including nuclear fuels, medical imaging, and semiconductors. Being incorporated in 2021, ASP Isotopes is a relatively young company with a focus on developing and commercializing advanced isotope separation technologies.

ASP Isotopes Inc. offers a range of isotopes and related services through its two business segments. Its key technologies include the Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE), which are used to separate gas species and isotopes in a volatile state. The company produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. It also develops Zinc-68, Nickel-64, and Xenon-129/136 for nuclear medicine, as well as Lithium-7, Uranium-235, and Chlorine-37 for the energy industry, and Germanium-70/72/74 for semiconductor markets. Additionally, the company provides related services and operates PET labs. Its portfolio targets end markets such as pharmaceuticals, agrochemicals, nuclear medical imaging, and semiconductors.